Pimavanserin's Potential in Lewy Body Dementia

Pimavanserin is recognized for its approval in treating Parkinson's disease psychosis, specifically targeting hallucinations. Given the similarities in pathology between Lewy body dementia and Parkinson's disease, it is theorized that pimavanserin may also offer therapeutic benefits for visual hallucinations and agitation associated with Lewy body dementia, although this would be considered off-label use. Multiple speakers at the conference highlighted that increased dopamine across various disorders can contribute to psychosis. Thus, manipulating serotonin levels through the blockade of the 2A receptor with drugs like pimavanserin may potentially reduce dopamine levels and mitigate psychotic symptoms.